Home > Formulary : Adult > Recent Decisions > 2015 >
Decisions 21st April 2015
At the meeting that took place on 21st April, the following decisions were agreed:
New Drug Requests
Approved
Sterculia and Frangula (Normacol Plus®) (TLS Bue)
- Approved for inclusion onto the formulary
Aclidinium and formoterol (Duaklir Genuair®) (TLS Blue)
- Approved for inclusion onto the formulary.
Shared Care Protocols/TLS Change in Status
Rifaximin
- The JFG agreed for the TLS change to amber 3 months. A SCP will need to be developed across BNSSG before the change is implemented in the formulary.
Fosfomycin
- Agreed for the TLS to change to TLS amber (specialist recommendation, no SCP). A GP may prescribe after recommendation from a microbiologist.
Pivmecillinam
- Agreed for the restrictions to be removed so it maybe prescribed in line with antibiotic guidance.
Rheumatology SCPs
- Updated SCPs agreed.
Stalevo®/Sastravi®
- Agreed for the TLS to change to amber (specialist recommendation, no SCP)
Entacapone
- Agreed for the TLS to change to amber (specialist recommendation, no SCP)
Rasagiline
- Agreed for the TLS to change to amber (specialist recommendation, no SCP)
Other decisions
Linaclotide
A review of the current prescribing was presented. The JFG agreed for linaclotide to remain formulary and to remain amber 1 month currently.
Overactive Bladder drugs review
A public health review of the literature was presented. It was agreed for this to be disseminated further and for the plan to work on and agree a BNSSG OAB treatment pathway.